Primary Hyperparathyroidism Manifesting with Severe Hypercalcemia in a Nonagenarian Man: Pitfall of Common Imaging Techniques, Localization by 18F-Choline Positron Emission Tomography/Computed Tomography and Successful Management with Calcimimetics
Language English Country Czech Republic Media print
Document type Case Reports, Journal Article
PubMed
32036848
DOI
10.14712/18059694.2020.5
PII: am_2019062040156
Knihovny.cz E-resources
- Keywords
- 18F-Choline PET/CT, cinacalcet, hypercalcemia, primary hyperparathyroidism,
- MeSH
- Choline MeSH
- Cinacalcet therapeutic use MeSH
- Hypercalcemia etiology MeSH
- Calcimimetic Agents therapeutic use MeSH
- Humans MeSH
- Positron Emission Tomography Computed Tomography methods MeSH
- Hyperparathyroidism, Primary complications diagnostic imaging drug therapy MeSH
- Radiopharmaceuticals MeSH
- Fluorine Radioisotopes MeSH
- Aged, 80 and over MeSH
- Severity of Illness Index MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Names of Substances
- Choline MeSH
- Cinacalcet MeSH
- Fluorine-18 MeSH Browser
- Calcimimetic Agents MeSH
- Radiopharmaceuticals MeSH
- Fluorine Radioisotopes MeSH
A nonagenarian hypertensive man with chronic kidney disease (CKD) was admitted to the emergency department for gastrointestinal symptoms and worsening symptoms of depression. Severe hypercalcemia (15.3 mg/dL) was found and he was hospitalized. Fluids, loop diuretics and glucocorticoids were administered intravenously, which partially reduced calcium levels over a few days and improved his clinical condition. PTH levels proved increased (306 pg/mL) and 25-OHD levels were reduced; primary hyperparathyroidism (PHPT) was diagnosed. Neck ultrasonography (USG) did not show parathyroid enlargement, nor did 99mTechnetium-sestamibi (SESTAMIBI) scintigraphy reveal hyperfunctioning parathyroid glands. By contrast, 18F-choline PET/CT evidenced a nodule located close to the oesophagus, behind the right thyroid lobe, which proved compatible with a hyperfunctioning parathyroid gland. Since the patient declined surgery, and zoledronate was unfit owing to areas of rarefaction of the jaw, the calcimimetic cinacalcet was started; the dosage was progressively titrated up to 120 mg/day with normalisation of calcium levels over time. PTH levels, however, proved erratic and showed an upward trend over the first year of therapy; however its levels partially decreased following increase of vitamin D levels by replacement therapy. Cinacalcet is a useful and safe drug, which can normalise calcium levels and improve the clinical condition, even in very old patients with severe PHPT who decline or are unfit for surgery.
References provided by Crossref.org